ADMA Biologics, Inc.
ADMA
$17.02
$0.110.65%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 382.81M | 330.24M | 283.18M | 258.22M | 234.29M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 382.81M | 330.24M | 283.18M | 258.22M | 234.29M |
| Cost of Revenue | 195.50M | 177.94M | 171.64M | 169.27M | 162.26M |
| Gross Profit | 187.31M | 152.30M | 111.54M | 88.94M | 72.03M |
| SG&A Expenses | 70.00M | 65.61M | 63.64M | 63.29M | 66.05M |
| Depreciation & Amortization | 550.50K | 701.50K | 738.50K | 724.50K | 715.50K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 267.92M | 246.30M | 238.91M | 236.58M | 232.95M |
| Operating Income | 114.89M | 83.94M | 44.27M | 21.63M | 1.34M |
| Income Before Tax | 73.36M | 39.17M | -3.05M | -28.24M | -22.83M |
| Income Tax Expenses | 5.22M | 4.38M | 595.00K | -- | -- |
| Earnings from Continuing Operations | 68.13 | 34.79 | -3.64 | -28.24 | -22.83 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 68.13M | 34.79M | -3.64M | -28.24M | -22.83M |
| EBIT | 114.89M | 83.94M | 44.27M | 21.63M | 1.34M |
| EBITDA | 123.09M | 92.29M | 52.67M | 29.96M | 9.50M |
| EPS Basic | 0.29 | 0.15 | -0.02 | -0.13 | -0.11 |
| Normalized Basic EPS | 0.27 | 0.18 | 0.06 | -0.01 | -0.07 |
| EPS Diluted | 0.28 | 0.14 | -0.02 | -0.13 | -0.11 |
| Normalized Diluted EPS | 0.26 | 0.17 | 0.06 | -0.01 | -0.07 |
| Average Basic Shares Outstanding | 921.83M | 912.54M | 902.80M | 895.85M | 872.71M |
| Average Diluted Shares Outstanding | 949.35M | 938.31M | 918.83M | 904.33M | 881.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
